The Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma and Innoviva
For Immediate Release
Chicago, IL – September 14, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mylan N.V. (MYL), ANI Pharmaceuticals, Inc. (ANIP), Cambrex Corp. (CBM), PDL BioPharma (PDLI) and Innoviva, Inc. ( INVA).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday’s Analyst Blog:
4 Biotech Stocks to Buy as Election Fever Rises
Despite recent events, Hillary Clinton maintains her lead over Trump and remains widely anticipated to win the race to the White House. Positions of both candidates on a variety of issues have been discussed with great detail. For instance, Clinton has continued to emphasize that the pharma industry and biotech companies in particular require greater regulation.
As a result of this stance and other issues, biotech stocks suffered losses throughout the year. However, the sector’s stocks enjoyed a rare day of gains on Monday, the strongest in months. This underlines the fact that the sector may continue to enjoy gains and enjoys strong long term potential. Adding select stocks from the sector to your portfolio could still make for a smart choice.
Clinton Protests Price Hikes
Rising drug prices first raised Clinton’s ire in Sep 2015. Her “price gouging” tweet led to a major sell-off thereby cutting short the phenomenal run of health care stocks, particularly in the biotech sector. While Clinton expressed concerns over the entire industry’s pricing practices, the tweet was primarily in response to Turing raising the price of Daraprim from $13.50 to $750 per pill in a single shot.
Matters have not been helped by Clinton’s recent tweet on a similar issue. Toward the end of August, a couple of U.S. senators raised questions about Mylan N.V. (MYL) over pricing epinephrine auto-injector EpiPen. Making matter worse, Clinton posted a tweet, saying “EpiPens can be the difference between life and death. There's no justification for these price hikes." (Read: Forget Mylan, Buy These 3 Drug Stocks Instead )
Sector Still Sports Strengths
Primarily due to price related concerns, the iShares Nasdaq Biotechnology (IBB) was down 20% year-to-date at the beginning of Feb 2016. Even now the sector remains in the red and has lost around 15% since the start of the year. However, the biotech sector remains a good option for investors who are looking for investment opportunities which have little relationship with the direction the economy is taking.
Additionally, most of the sector’s losses came toward the beginning of the year. Now, stocks from this industry can only perform better. Though drug pricing will continue to be an important issue, other developments will also make their impact felt. Biosimilars are likely to gain prominence and provide the industry with a new avenue of growth.
Further, as valuations become more attractive the rest of the year could also witness the announcement of several mergers and acquisitions. Products which received approval last year are also likely to substantially add to revenues.
Our Choices
Despite the year’s reverses, biotech stocks continue to have inherent strengths. The worst could be over for the sector and it may now be poised to make a turnaround.
This is why it makes sense to pick biotech stocks at this point. We have narrowed down our search to the following stocks based on a good Zacks Rank and other relevant metrics.
ANI Pharmaceuticals, Inc. (ANIP) is involved in developing, manufacturing and marketing generic and branded pharma products in the U.S.
ANI Pharmaceuticals has a Zacks Rank #1 (Strong Buy).The company has expected earnings growth of 55.5% for the current year. It has a P/E (F1) of 16.79.
Cambrex Corp. (CBM) is a provider of a variety of products utilized in the development and commercialization of new and generic drugs across the world.
Cambrex has a Zacks Rank #1. The company has expected earnings growth of 39.8% for the current year. The forward price-to-earnings (P/E) ratio for the current financial year (F1) is 18.50.
PDL BioPharma (PDLI) is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer.
PDL BioPharma’s earnings estimate for the current year has improved by 20.4% over the last 30 days. The forward price-to-earnings (P/E) ratio for the current financial year (F1) is 4.57. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Innoviva, Inc. (INVA) is focused on the development, commercialization and financial management of bio-pharmaceuticals.
Innoviva has a Zacks Rank #2. The company has expected earnings growth of more than 100% for the current year. The forward price-to-earnings (P/E) ratio for the current financial year (F1) is 19.47.
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYLAN NV (MYL): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
PDL BIOPHARMA (PDLI): Free Stock Analysis Report
INNOVIVA INC (INVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
